← Back to Search

Shared Care for Other Cancers

N/A
Waitlist Available
Led By Gregory A. Abel, MD MPH
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will help researchers learn if it's better for people who've had a hematopoietic cell transplant to see a local oncologist or the transplant center for follow-up care.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
100-day non-relapse mortality (NRM) for patients in Shared Care versus Usual Care
Highly-relevant PROs for Shared versus Usual Care at 180 days post-HCT
Secondary outcome measures
Overall Survival
cGVHD

Trial Design

3Treatment groups
Experimental Treatment
Group I: Usual CareExperimental Treatment1 Intervention
Patients receive all follow-up care at DFCI only, which is currently the Standard Care. Majority of routine visits in first 180 days will be at DFCI.
Group II: Shared CareExperimental Treatment1 Intervention
For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits. From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks. Shared Care include the following Formal Care Coordination Plan Patient Engagement and Education Local Oncologist Engagement and Education Patient/Local Oncologist/Transplant Oncologist Web Portal
Group III: Non-RandomizedExperimental Treatment1 Intervention
Patients receive all follow-up care at DFCI only (Standard Care).

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,079 Previous Clinical Trials
340,544 Total Patients Enrolled
5 Trials studying Other Cancers
55,147 Patients Enrolled for Other Cancers
Gregory A. Abel, MD MPHPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Columbia University College Of Physicians And Surgeons (Medical School)
Mass Gen Hospital (Residency)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation
Gregory A. Abel, MD 2018. "Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03244826.
~56 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top